These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27473047)

  • 1. The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.
    Lange AE; Thyrian JR; Wetzka S; Flessa S; Hoffmann W; Zygmunt M; Fusch C; Lode HN; Heckmann M
    BMC Pregnancy Childbirth; 2016 Jul; 16(1):197. PubMed ID: 27473047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of congenital toxoplasmosis in Slovenia by serological screening of pregnant women.
    Logar J; Petrovec M; Novak-Antolic Z; Premru-Srsen T; Cizman M; Arnez M; Kraut A
    Scand J Infect Dis; 2002; 34(3):201-4. PubMed ID: 12030394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for toxoplasmosis in pregnancy: what is the evidence of reducing a health problem?
    Eskild A; Oxman A; Magnus P; Bjørndal A; Bakketeig LS
    J Med Screen; 1996; 3(4):188-94. PubMed ID: 9041483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria.
    Aspöck H; Pollak A
    Scand J Infect Dis Suppl; 1992; 84():32-7. PubMed ID: 1290071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coverage and outcomes of antenatal tests for infections: a population based survey in the Province of Trento, Italy.
    Dalmartello M; Parazzini F; Pedron M; Pertile R; Collini L; La Vecchia C; Piffer S
    J Matern Fetal Neonatal Med; 2019 Jun; 32(12):2049-2055. PubMed ID: 29343192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Avidity of IgG anti-Toxoplasma gondii. Study to establish a new decision tree for screening].
    Pfister P; Dromigny JA
    Arch Inst Pasteur Madagascar; 2001; 67(1-2):57-60. PubMed ID: 12471751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How can the cost of screening for toxoplasmosis during pregnancy be reduced?].
    Ancelle T; Yera H; Talabani H; Lebuisson A; Thulliez P; Dupouy-Camet J
    Rev Epidemiol Sante Publique; 2009 Dec; 57(6):411-7. PubMed ID: 19932576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.
    Stillwaggon E; Carrier CS; Sautter M; McLeod R
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1333. PubMed ID: 21980546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of screening for toxoplasmosis during pregnancy.
    Lappalainen M; Sintonen H; Koskiniemi M; Hedman K; Hiilesmaa V; Ammälä P; Teramo K; Koskela P
    Scand J Infect Dis; 1995; 27(3):265-72. PubMed ID: 8539552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxoplasmosis in pregnancy: prevention, screening, and treatment.
    Paquet C; Yudin MH;
    J Obstet Gynaecol Can; 2013 Jan; 35(1):78-81. PubMed ID: 23343802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for toxoplasmosis in pregnant women: presentation of a screening programme in the former "East"-Germany, and the present status in Germany.
    Hengst P
    Scand J Infect Dis Suppl; 1992; 84():38-42. PubMed ID: 1290072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal diagnosis and prevention of toxoplasmosis in pregnant women in Northern Vietnam: study protocol.
    Smit GSA; Vu TLB; Do TD; Speybroeck N; Devleesschauwer B; Padalko E; Roets E; Dorny P
    BMC Infect Dis; 2017 May; 17(1):364. PubMed ID: 28545476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal screening of pregnant women for infections caused by cytomegalovirus, Epstein-Barr virus, herpesvirus, rubella, and Toxoplasma gondii.
    Hunter K; Stagno S; Capps E; Smith RJ
    Am J Obstet Gynecol; 1983 Feb; 145(3):269-73. PubMed ID: 6297301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital toxoplasmosis: is screening desirable?
    Foulon W
    Scand J Infect Dis Suppl; 1992; 84():11-7. PubMed ID: 1290068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological survey and risk factors associated with
    Zakari MM; Isah AY; Offiong R; Yunusa T; Abdullahi IN
    Malawi Med J; 2020 Sep; 32(3):160-167. PubMed ID: 33488988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and prevention of congenital toxoplasmosis: an effectiveness study in a population with a high infection rate.
    Ricci M; Pentimalli H; Thaller R; Ravà L; Di Ciommo V
    J Matern Fetal Neonatal Med; 2003 Dec; 14(6):398-403. PubMed ID: 15061319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal factors influencing late entry into prenatal care: a stratified analysis by race or ethnicity and insurance status.
    Baer RJ; Altman MR; Oltman SP; Ryckman KK; Chambers CD; Rand L; Jelliffe-Pawlowski LL
    J Matern Fetal Neonatal Med; 2019 Oct; 32(20):3336-3342. PubMed ID: 29631462
    [No Abstract]   [Full Text] [Related]  

  • 18. Serological screening for toxoplasmosis in pregnancy in Slovenia.
    Logar J; Novak-Antolic Z; Zore A
    Scand J Infect Dis; 1995; 27(2):163-4. PubMed ID: 7660082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of suspected primary Toxoplasma gondii infection in pregnant women in Norway: twenty years of experience of amniocentesis in a low-prevalence population.
    Findal G; Helbig A; Haugen G; Jenum PA; Stray-Pedersen B
    BMC Pregnancy Childbirth; 2017 Apr; 17(1):127. PubMed ID: 28441952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study.
    Koskiniemi M; Lappalainen M; Koskela P; Hedman K; Ammälä P; Hiilesmaa V; Teramo K
    Scand J Infect Dis Suppl; 1992; 84():70-4. PubMed ID: 1290079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.